Al Qassimi Hospital pioneers pulmonary hypertension therapy
The three successful surgeries represent a significant departure from traditional drug-based therapies, providing patients with a more effective and lasting option. A local team collaborated with Chinese professionals to carry out the treatment, which was approved by European regulators and used in about 1,000 cases globally. The next day, the doctors discharged all patients in stable health.
A step towards enhancing patients' quality of life
Dr Arif Al Nooryani, Director of Al Qassimi Hospital in Sharjah, described the achievement as a significant step forward in improving care for patients with chronic, difficult diseases. He emphasised the hospital's dedication to using modern therapies and enabling local medical staff to provide world-class care.
Vast aspirations for national healthcare
This victory improves the UAE's leadership in advanced healthcare and contributes to national goals under "We the UAE 2031" and Centennial 2071.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Arabian Post
2 days ago
- Arabian Post
Shanghai Healthcare M&A Fund Takes Strategic Stake in MicroPort Scientific Corporation
HONG KONG SAR – Media OutReach Newswire – 25 July 2025 – MicroPort Scientific Corporation (Stock Code: 'MicroPort') announced that Shanghai Healthcare M&A Fund ('SHMAF'), a fund managed by SIIC Capital, a subsidiary of SIIC Group, has entered into a share purchase agreement to acquire 135,335,204 shares in MicroPort held by Otsuka Medical Devices Co., Ltd. Through this transaction, SHMAF will become a strategic shareholder in MicroPort, underscoring its role as a state-backed, professionally operated platform that is creating value and empowering, stabilizing, developing, and reshaping leading biopharmaceutical companies in China. As a homegrown Chinese innovator that has grown into a global leader in high-end medical devices, MicroPort serves as an anchor company for the industry. Its stable development is critical to both China's and the global high-end medical device supply chain. This investment reflects SHMAF's capital-driven approach to providing crucial support to domestic anchor companies, ensuring their stability and support growth of their core assets. SHMAF will support MicroPort's growth momentum and high-quality sustainable development with its expansive resources. Introducing a strategic shareholder to drive growth momentum. The transaction brings in a significant strategic shareholder for MicroPort. Leveraging its state-backed resources and industrial expertise, SHMAF will support MicroPort's development needs, core business expansion, and potential strategic mergers and acquisitions to create synergies that bolster the company's ongoing innovation and scale-up its operations. ADVERTISEMENT Optimizing resource allocation to unlock synergistic value. MicroPort has successfully incubated and nurtured multiple listed companies and specialized, highly influential small companies, in the process establishing a unique MicroPort ecosystem. SHMAF will leverage its capital and operational integration expertise to support MicroPort in refining its development strategy, optimizing resource allocation, and unlocking synergistic value—while fully respecting market dynamics and corporate autonomy—to further strengthen its ecosystem and competitive advantages. Enhancing ecosystem to enhance anchor company value. MicroPort's product portfolio spans across ten major verticals, including cardiovascular intervention, rhythm management, orthopaedics, neurovascular intervention, and surgical robotics, making it a core player in the high-end medical device industrial chain. SHMAF's support will not only drive MicroPort's growth, it will also accelerate its consolidation of upstream and downstream companies in Shanghai, attract highly-skilled talent, and facilitate breakthroughs in critical technologies and core components—ultimately enhancing the global competitiveness of China's high-end medical device industry. This transaction marks another significant step in SHMAF's commitment to serving biopharmaceutical anchor companies. Upholding its value investment principles, SHMAF will collaborate with MicroPort's shareholders and management team to leverage the strategic support and industrial synergies its state-backed platform offers. Together, they will reinforce MicroPort's position as China's innovation engine in high-end medical devices and contribute to the advancement of the biopharmaceutical industry. Hashtag: #SIICCapital #MicroPort #SHMAF The issuer is solely responsible for the content of this announcement. About MicroPort Scientific Corporation Founded in 1998 and headquartered in Shanghai's Zhangjiang, MicroPort Scientific Corporation is a leading domestic innovative high-end medical device group. It began by breaking the import monopoly in the cardiovascular stent field, and after 26 years of innovative development, its business has expanded to areas including rhythm management, orthopaedics, cardiovascular intervention, aortic and peripheral vascular intervention, neurovascular intervention, heart valves, surgical robots, and surgical medical devices. By the end of 2024, MicroPort operated in over 20,000 hospitals across 100 countries and regions worldwide, providing more than 600 solutions for patients covering over 200 diseases. MicroPort has incubated 6 A-share and Hong Kong-listed companies, owns 9 specialized and sophisticated SMEs, 4 technology giant enterprises, and 16 national high-tech enterprises, making it an outstanding representative of Shanghai's technological innovation and industrial transformation. About SIIC Capital As the active fund management platform under SIIC Group, since its establishment, SIIC Capital has been based in Shanghai, connected with Hong Kong, and oriented towards the world, actively exploring investment opportunities in strategic emerging industries such as biomedicine and green environmental protection. Through a multi-currency, full-stage fund matrix layout, it deeply serves national strategies and the construction of biomedicine highlands.
Gulf Today
3 days ago
- Gulf Today
I keep waking up at 4am. Is it stress, or something else?
Charlotte Cripps, The Independent Why do I randomly wake up at the same time each night? It's always 4am on the dot. I'm starting to wonder if it has some special significance – beyond sheer annoyance. I've tried eyemasks. Relaxation techniques. Electrolyte sachets with added magnesium. Nothing works. Every night: 4am. A 2021 study titled The Different Faces of Insomnia found that 40 per cent of us experience early morning waking, and have trouble falling back to sleep again. The typical reasons trotted out often include the insomnia, stress, ageing, medications, diet, and pain. But, lying awake in the quiet of the night researching my problem, I come across another, altogether more exotic explanation: the spirit world. According to folklore, the 'witching hour', variably said to be between midnight and 4am, is when the veil between the living and the spirit world is believed to be paper-thin, making communication with spirits easier; waking up signals that you are spiritually in tune. It may, if you believe such things, indicate astral travel — the soul returning to the body after traversing other universes. My penchant for 4am rousings might mean that spirit guides are sending important messages, or guiding me towards my destiny. In desperation, I decided to look into the woo-woo rationale behind these claims, as well as the more scientific explanations, in the hope I might find a solution. If that means accepting that a guardian angel is trying to alert me to important news, or that my racing mind is egged on by an overactive third eye chakra, then so be it. I don't want to knock myself out with sleeping pills — or scroll the news headlines on my phone at dawn. A-list acupuncturist Ross Barr, who runs sessions out of Claridge's Spa, has a client list that includes Prince Harry and Meghan Markle, both of whom had regular appointments with him as part of their pre-wedding wellness routine. Repeatedly waking at a particular time, Barr tells me, has huge significance. 'It is rarely random. Eastern medicine figured out long ago,' he says. 'It's often a clue pointing to a possible imbalance in a specific organ or an underlying emotional cause.' According to the traditional Chinese medicine (TCM) organ clock, each three-hour window is linked to a different organ system. Waking at 1am to 3am, Barr tells me, is liver time. 'It's often associated with internal heat, frustration, stress, or alcohol,' he says. Waking between 3am and 5am, meanwhile, signals issues with the lungs. '(It's) more about grief and loss, or typical lung pathology like asthma.' But waking too early before your alarm can also suggest that you're running on adrenaline, he says. 'It's like your body is bracing for something, as if it's trying to get ahead of danger or the day itself.' Others believe that imbalanced chakras — energy centres thought to govern different physical and emotional functions — are the culprit. The third eye, which is related to intuition and sleep regulation, and root chakra, associated with feelings of security and grounding, are often linked with sleep disturbances like insomnia or restless sleep. 'At around 4am, the throat and the heart chakras are functioning at their strongest,' says Padma Coram, a spiritual and integrative lifestyle and wellness expert at London's Hale Clinic. She claims that if the seven chakras are not flowing freely along the spine, from the base to the crown of the head, the body wakes up to alert you to fix the problem. 'It's not just sleep disturbance — it's the soul gently tapping or knocking. The body is trying to get your attention through the subconscious.' In my case, she says, waking at 4am repeatedly could mean there's unspoken emotion, suppressed grief, or a truth that needs to be expressed. She advises facing problems head-on. 'We either want to stick our heads under the sand, we get irritable, angry and highly strung, or want to go out to get distracted,' she says, 'but it's important to voice our concerns even if it's just to ourselves, so that the mind and body can process them.'
Al Etihad
6 days ago
- Al Etihad
AstraZeneca says to invest $50 billion in the US
22 July 2025 11:25 LONDON (AFP)British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States amid a looming deadline of ramped-up tariffs from Washington.A large chunk of the funds will go toward building a multi-billion-dollar manufacturing centre in Virginia, the company said in a statement, adding that it expects 50 percent of its revenue to come from the United States by 2030."Today's announcement underpins our belief in America's innovation in biopharmaceuticals," the statement quoted CEO Pascal Soriot as President Donald Trump has opened the door to potential tariffs targeting pharmaceuticals, which have so far benefited from exemptions to his sweeping levies on imports from trading ordered an investigation launched into pharmaceutical imports, suggesting that levies could reach up to 200 United States is a key market for the pharmaceutical industry, and AstraZeneca had already announced in April that it had begun transferring part of its European production to the United States. "For decades Americans have been reliant on foreign supply of key pharmaceutical products," US Commerce Secretary Howard Lutnick said in a added that the new tariffs are focused on "ending this structural weakness."The announcement included a new factory in Virginia, which will be the company's "largest single manufacturing investment." Other major pharmaceutical companies, which had been exempt from tariffs for 30 years, have, in recent months, begun shifting investment and production to the United States.
